Oncoprotein E7 from beta human papillomavirus 38 induces formation of an inhibitory complex for a subset of p53-regulated promoters

Journal of Virology

Volumn 87, Issue 22, 2013, Pages 12139-12150

  Saidj, Djamel ^a   Cros, Marie Pierre ^a   Hernandez Vargas, Hector ^a   Guarino, Francesca ^b   Sylla, Bakary S ^a   Tommasino, Massimo ^a   Accardi, Rosita ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b UNIVERSITY OF CATANIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DNA METHYLTRANSFERASE 1; HISTONE H3; I KAPPA B KINASE BETA; PROTEIN E7; PROTEIN P53; TRANSCRIPTION FACTOR EZH2; DNA (CYTOSINE 5) METHYLTRANSFERASE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE 1; DNA BINDING PROTEIN; EZH2 PROTEIN, HUMAN; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LUCIFERASE; MESSENGER RNA; NUCLEAR PROTEIN; POLYCOMB REPRESSIVE COMPLEX 2; SMALL INTERFERING RNA; TP53 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN P73;

APOPTOSIS; ARTICLE; BETA HUMAN PAPILLOMAVIRUS 38; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; DNA METHYLATION; DNA REPAIR; EPIGENETICS; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; HISTONE METHYLATION; HUMAN; HUMAN CELL; KERATINOCYTE; PIG3 GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; VIRUS GENE; WART VIRUS; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CFU COUNTING; CYTOLOGY; FIBROBLAST; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; IMMUNOPRECIPITATION; METABOLISM; MOUSE; PAPILLOMA VIRUS; PAPILLOMAVIRUS INFECTION; PATHOLOGY; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIROLOGY; WESTERN BLOTTING;

HUMAN PAPILLOMAVIRUS TYPE 38;

ANIMALS; BLOTTING, WESTERN; CELLS, CULTURED; CHROMATIN IMMUNOPRECIPITATION; COLONY-FORMING UNITS ASSAY; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA-BINDING PROTEINS; FIBROBLASTS; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; I-KAPPA B KINASE; IMMUNOPRECIPITATION; KERATINOCYTES; LUCIFERASES; MICE; NF-KAPPA B; NUCLEAR PROTEINS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; POLYCOMB REPRESSIVE COMPLEX 2; PROMOTER REGIONS, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 84886259193     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01047-13     Document Type: Article

References (46)

1. Bouvard V, Gabet AS, Accardi R, Sylla SB, Tommasino M. 2006. The cutaneous human papillomavirus types and non-melanoma-skin cancer, p 269-277. In Campo MS (ed), Papillomavirus research: from natural history to vaccine and beyond. Caister Academic Press, Norfolk, United Kingdom.
2. Pfister H, Fuchs PG, Majewski S, Jablonska S, Pniewska I, Malejczyk M. 2003. High prevalence of epidermodysplasia verruciformis-associated human papillomavirus DNA in actinic keratoses of the immunocompetent population. Arch. Dermatol. Res. 295:273-279.
3. Accardi R, Dong W, Smet A, Cui R, Hautefeuille A, Gabet AS, Sylla BS, Gissmann L, Hainaut P, Tommasino M. 2006. Skin human papillomavirus type 38 alters p53 functions by accumulation of ΔNp73. EMBO Rep. 7:334-340.
4. Caldeira S, Zehbe I, Accardi R, Malanchi I, Dong W, Giarre M, de Villiers EM, Filotico R, Boukamp P, Tommasino M. 2003. The E6 and E7 proteins of the cutaneous human papillomavirus type 38 display transforming properties. J. Virol. 77:2195-2206.
5. Dong W, Kloz U, Accardi R, Caldeira S, Tong WM, Wang ZQ, Jansen L, Durst M, Sylla BS, Gissmann L, Tommasino M. 2005. Skin hyperproliferation and susceptibility to chemical carcinogenesis in transgenic mice expressing E6 and E7 of human papillomavirus type 38. J. Virol. 79:14899-14908.
6. Gabet AS, Accardi R, Bellopede A, Popp S, Boukamp P, Sylla BS, Londono-Vallejo JA, Tommasino M. 2008. Impairment of the telomere/telomerase system and genomic instability are associated with keratinocyte immortalization induced by the skin human papillomavirus type 38. FASEB J. 22:622-632.
7. Howie HL, Koop JI, Weese J, Robinson K, Wipf G, Kim L, Galloway DA. 2011. Beta-HPV 5 and 8 E6 promote p300 degradation by blocking AKT/p300 association. PLoS Pathog. 7:e1002211. doi:10.1371/journal.ppat.1002211.
8. Michel A, Kopp-Schneider A, Zentgraf H, Gruber AD, de Villiers EM. 2006. E6/E7 expression of human papillomavirus type 20 (HPV-20) and HPV-27 influences proliferation and differentiation of the skin in UVirradiated SKH-hr1 transgenic mice. J. Virol. 80:11153-11164.
9. Muench P, Probst S, Schuetz J, Leiprecht N, Busch M, Wesselborg S, Stubenrauch F, Iftner T. 2010. Cutaneous papillomavirus E6 proteins must interact with p300 and block p53-mediated apoptosis for cellular immortalization and tumorigenesis. Cancer Res. 70:6913-6924.
10. Muschik D, Braspenning-Wesch I, Stockfleth E, Rosl F, Hofmann TG, Nindl I. 2011. Cutaneous HPV23 E6 prevents p53 phosphorylation through interaction with HIPK2. PLoS One 6:e27655. doi:10.1371/journal.pone.0027655.
11. Schaper ID, Marcuzzi GP, Weissenborn SJ, Kasper HU, Dries V, Smyth N, Fuchs P, Pfister H. 2005. Development of skin tumors in mice transgenic for early genes of human papillomavirus type 8. Cancer Res. 65: 1394-1400.
12. Wallace NA, Robinson K, Howie HL, Galloway DA. 2012. HPV 5 and 8 E6 abrogate ATR activity resulting in increased persistence of UVB induced DNA damage. PLoS Pathog. 8:e1002807. doi:10.1371/journal.ppat.1002807.
13. Viarisio D, Mueller-Decker K, Kloz U, Aengeneyndt B, Kopp-Schneider A, Grone HJ, Gheit T, Flechtenmacher C, Gissmann L, Tommasino M. 2011. E6 and E7 from beta HPV38 cooperate with ultraviolet light in the development of actinic keratosis-like lesions and squamous cell carcinoma in mice. PLoS Pathog. 7:e1002125. doi:10.1371/journal.ppat.1002125.
14. Accardi R, Scalise M, Gheit T, Hussain I, Yue J, Carreira C, Collino A, Indiveri C, Gissmann L, Sylla BS, Tommasino M. 2011. IκB kinase beta promotes cell survival by antagonizing p53 functions through ΔNp73α phosphorylation and stabilization. Mol. Cell. Biol. 31:2210-2226.
15. Dong W, Arpin C, Accardi R, Gissmann L, Sylla BS, Marvel J, Tommasino M. 2008. Loss of p53 or p73 in human papillomavirus type 38 E6 and E7 transgenic mice partially restores the UV-activated cell cycle checkpoints. Oncogene 27:2923-2928.
16. Buhlmann S, Putzer BM. 2008. DNp73 a matter of cancer: mechanisms and clinical implications. Biochim. Biophys. Acta 1785:207-216.
17. Melino G, De Laurenzi V, Vousden KH. 2002. p73: friend or foe in tumorigenesis. Nat. Rev. Cancer 2:605-615.
18. Melino G, Lu X, Gasco M, Crook T, Knight RA. 2003. Functional regulation of p73 and p63: development and cancer. Trends Biochem. Sci. 28:663-670.
19. Petrenko O, Zaika A, Moll UM. 2003. deltaNp73 facilitates cell immortalization and cooperates with oncogenic Ras in cellular transformation in vivo. Mol. Cell. Biol. 23:5540-5555.
20. Stiewe T, Zimmermann S, Frilling A, Esche H, Putzer BM. 2002. Transactivation-deficient ΔTA-p73 acts as an oncogene. Cancer Res. 62: 3598-3602.
21. Wilhelm MT, Rufini A, Wetzel MK, Tsuchihara K, Inoue S, Tomasini R, Itie-Youten A, Wakeham A, Arsenian-Henriksson M, Melino G, Kaplan DR, Miller FD, Mak TW. 2010. Isoform-specific p73 knockout mice reveal a novel role for ΔNp73 in the DNA damage response pathway. Genes Dev. 24:549-560.
22. Casciano I, Banelli B, Croce M, Allemanni G, Ferrini S, Tonini GP, Ponzoni M, Romani M. 2002. Role of methylation in the control of ΔNp73 expression in neuroblastoma. Cell Death Differ. 9:343-345.
23. Fillippovich I, Sorokina N, Gatei M, Haupt Y, Hobson K, Moallem E, Spring K, Mould M, McGuckin MA, Lavin MF, Khanna KK. 2001. Transactivation-deficient p73α (p73Δexon2) inhibits apoptosis and competes with p53. Oncogene 20:514-522.
24. Stiewe T, Putzer BM. 2002. Role of p73 in malignancy: tumor suppressor or oncogene? Cell Death Differ. 9:237-245.
25. Accardi R, Fathallah I, Gruffat H, Mariggio G, Le Calvez-Kelm F, Voegele C, Bartosch B, Hernandez-Vargas H, McKay J, Sylla BS, Manet E, Tommasino M. 2013. Epstein-Barr virus transforming protein LMP-1 alters B cells gene expression by promoting accumulation of the oncoprotein ΔNp73α. PLoS Pathog. 9:e1003186. doi:10.1371/journal.ppat.1003186.
26. Allart S, Martin H, Detraves C, Terrasson J, Caput D, Davrinche C. 2002. Human cytomegalovirus induces drug resistance and alteration of programmed cell death by accumulation of ΔN-p73α. J. Biol. Chem. 277: 29063-29068.
27. Morgenstern JP, Land H. 1990. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res. 18: 3587-3596.
28. Fu L, Lin-Lee YC, Pham LV, Tamayo AT, Yoshimura LC, Ford RJ. 2009. BAFF-R promotes cell proliferation and survival through interaction with IKKβ and NF-κB/c-Rel in the nucleus of normal and neoplastic B-lymphoid cells. Blood 113:4627-4636.
29. Contente A, Dittmer A, Koch MC, Roth J, Dobbelstein M. 2002. A polymorphic microsatellite that mediates induction of PIG3 by p53. Nat. Genet. 30:315-320.
30. Hussain I, Fathallah I, Accardi R, Yue J, Saidj D, Shukla R, Hasan U, Gheit T, Niu Y, Tommasino M, Sylla BS. 2011. NF-κB protects human papillomavirus type 38 E6/E7-immortalized human keratinocytes against tumor necrosis factor alpha and UV-mediated apoptosis. J. Virol. 85: 9013-9022.
31. Cornet I, Bouvard V, Campo MS, Thomas M, Banks L, Gissmann L, Lamartine J, Sylla BS, Accardi R, Tommasino M. 2012. Comparative analysis of transforming properties of E6 and E7 from different beta human papillomavirus types. J. Virol. 86:2366-2370.
32. Sun SC, Cesarman E. 2011. NF-κB as a target for oncogenic viruses. Curr. Top. Microbiol. Immunol. 349:197-244.
33. Tato CM, Hunter CA. 2002. Host-pathogen interactions: subversion and utilization of the NF-κB pathway during infection. Infect. Immun. 70: 3311-3317.
34. Sun SC, Harhaj EW, Xiao G, Good L. 2000. Activation of I-κB kinase by the HTLV type 1 Tax protein: mechanistic insights into the adaptor function of IKK. AIDS Res. Hum. Retrovir. 16:1591-1596.
35. Chen L, Meng Q, Kao W, Xia Y. 2011. IκB kinase beta regulates epithelium migration during corneal wound healing. PLoS One 6:e16132. doi: 10.1371/journal.pone.0016132.
36. Irelan JT, Murphy TJ, DeJesus PD, Teo H, Xu D, Gomez-Ferreria MA, Zhou Y, Miraglia LJ, Rines DR, Verma IM, Sharp DJ, Tergaonkar V, Chanda SK. 2007. A role for IκB kinase 2 in bipolar spindle assembly. Proc. Natl. Acad. Sci. U. S. A. 104:16940-16945.
37. Tsuchiya Y, Asano T, Nakayama K, Kato T, Jr, Karin M, Kamata H. 2010. Nuclear IKKβ is an adaptor protein for IκBα ubiquitination and degradation in UV-induced NF-κB activation. Mol. Cell 39:570-582.
38. Vire E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C, Morey L, Van Eynde A, Bernard D, Vanderwinden JM, Bollen M, Esteller M, Di Croce L, de Launoit Y, Fuks F. 2006. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439:871-874.
39. Levrero M, De Laurenzi V, Costanzo A, Gong J, Wang JY, Melino G. 2000. The p53/p63/p73 family of transcription factors: overlapping and distinct functions. J. Cell Sci. 113(Pt 10):1661-1670.
40. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D, Sewalt RG, Otte AP, Hayes DF, Sabel MS, Livant D, Weiss SJ, Rubin MA, Chinnaiyan AM. 2003. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl. Acad. Sci. U. S. A. 100:11606-11611.
41. Richter GH, Plehm S, Fasan A, Rossler S, Unland R, Bennani-Baiti IM, Hotfilder M, Lowel D, von Luettichau I, Mossbrugger I, Quintanilla-Martinez L, Kovar H, Staege MS, Muller-Tidow C, Burdach S. 2009. EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation. Proc. Natl. Acad. Sci. U. S. A. 106:5324-5329.
42. Robert MF, Morin S, Beaulieu N, Gauthier F, Chute IC, Barsalou A, MacLeod AR. 2003. DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nat. Genet. 33:61-65.
43. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA, Chinnaiyan AM. 2002. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419:624-629.
44. Yu J, Yu J, Rhodes DR, Tomlins SA, Cao X, Chen G, Mehra R, Wang X, Ghosh D, Shah RB, Varambally S, Pienta KJ, Chinnaiyan AM. 2007. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res. 67:10657-10663.
45. Widschwendter M, Fiegl H, Egle D, Mueller-Holzner E, Spizzo G, Marth C, Weisenberger DJ, Campan M, Young J, Jacobs I, Laird PW. 2007. Epigenetic stem cell signature in cancer. Nat. Genet. 39:157-158.
46. Paschos K, Allday MJ. 2010. Epigenetic reprogramming of host genes in viral and microbial pathogenesis. Trends Microbiol. 18:439-447.